CA-TALKDESK
Talkdesk®, Inc. , the global customer experience leader for customer-obsessed companies, today embarked on the next phase of growth after two years of significant momentum in executing toward its bold vision to provide a better way for organizations to unlock the promise and potential of great customer service. To mark this new stage in its corporate maturation, Talkdesk unveiled a new logo and tagline – Experience. A better way. – that reflects the company’s commitment to being at the forefront of customer experience (CX) innovation and its focus on empowering customers to build brand trust and loyalty through customized, personal interactions.
Talkdesk’s reimagined logo reflects its commitment to helping companies connect every engagement moment into customer journeys that are personalized, productive and profitable. The bold new corporate identity comprises a fresh purple color palette and updated brand elements, featuring inclusive and diverse visual representations and illustrations that reflect the importance of human connection. The company also relaunched its website in five new languages – Brazilian Portuguese, French, German, Portuguese and Spanish, and unveiled a powerful new international advertising campaign.
“Today is about retelling the Talkdesk story in a way that pays tribute to our legacy, embraces our commitment to diversity and giving back, and deeply connects our path forward to the thousands of Talkdesk customers and employees who made what is yet to come possible,” said Kathie Johnson, chief marketing officer, Talkdesk. “Every element of who we are represents the importance of the connection we help companies make with their customers, because every moment matters.”
Talkdesk today also introduced availability of two additions to Talkdesk CX Cloud™ designed to propel the company into its new wave of growth: Talkdesk Workspace , a customizable user interface, and Talkdesk Builder, a set of tools for unlimited and accelerated contact center customization across workspaces, routing, reporting and integrations. Since its inception, rapid innovation has been a Talkdesk hallmark – one applauded by both customers and industry leaders, and valued by enterprise customers worldwide.
“Ten years ago, Talkdesk founder Tiago Paiva saw how Salesforce had re-invented the CRM world and realized a similar revolution was imminent for the call center,” said Sheila McGee-Smith, founder and principal analyst, McGee-Smith Analytics, LLC. “Talkdesk has been a significant part of the industry-wide contact center transformation, helping to move the industry toward a true elastic cloud, with all the innovation power that brings for not just customers but the entire customer experience ecosystem.”
Over the past 24 months, Talkdesk achieved several significant milestones, including:
- An international expansion that extended the company’s footprint not only within Portugal, the United Kingdom and the United States, but also into Australia, Brazil, France, Germany, Ireland, Italy, the Netherlands, Southeast Asia and Spain
- A proven executive leadership team – which is 45% female – with experience at some of the technology industry’s leading companies, including AT&T, Cloudera, Oracle, Salesforce and SAP
- Bringing to market 20 innovations in the first 20 weeks of 2020, including solutions designed to help its customers through the pandemic
- Expansion and strengthening of its partner ecosystem of cloud distributors, resellers, marketplace and strategic alliance partners
- Launching industry specific solutions to help address the unique customer service challenges of financial services and insurance, healthcare and life sciences, retail and e-commerce, and travel and hospitality companies
- Raising Series C funding of $143 million, bringing the company’s valuation to more than $3 billion
- Positioned as a leader in the 2020 Gartner Cloud Contact Center as a Service (CCaaS) Magic Quadrant
- Positioned as a leader in the 2020 Forrester Wave for CCaaS
“Today marks an inflection point in Talkdesk history. Talkdesk was founded on the principle that there had to be a better way for companies to deliver exceptional customer service. We now have customers in every major region of the world who have transformed their end-customers’ experience into an immersive, personalized and profitable journey,” said Tiago Paiva, Talkdesk founder and chief executive officer. “Our cloud-native platform was one of many industry-firsts Talkdesk introduced to the contact center marketplace over its first decade, and our talented
development team is hard at work on the products that will define our next 10 years of audacious innovation.”
Additional Resources
- Read Kathie Johnson’s perspective on leading Talkdesk through transformation growth as the company’s first chief marketing officer
- Read the press release introducing Talkdesk Workspace, a customizable interface designed to enable a better way to deliver superior customer experiences in contact centers
- Learn more about the new Talkdesk brand
Social Networks
- Web: https://www.talkdesk.com
- Blog: https://www.talkdesk.com/blog/
- Twitter: https://twitter.com/Talkdesk
- LinkedIn: https://www.linkedin.com/company/talkdesk/
- Facebook: https://www.facebook.com/Talkdesk/
- Instagram: https://www.instagram.com/Talkdesk/
About Talkdesk
Talkdesk® is a global customer experience leader for customer-obsessed companies. Our contact center solution provides a better way for businesses and customers to engage with one another. Our speed of innovation and global footprint reflect our commitment to ensure businesses everywhere can deliver better customer experiences through any channel, resulting in higher customer satisfaction, cost savings and profitability. Talkdesk CX CloudTM is an end-to-end customer experience solution that combines enterprise scale with consumer simplicity. Over 1,800 innovative companies around the world, including IBM, Acxiom, Trivago, and Fujitsu partner with Talkdesk to deliver a better way to great customer experience. Learn more and request a demo at www.talkdesk.com .
Talkdesk is a registered trademark of Talkdesk, Inc. All product and company names are trademarks ™ or registered ® trademarks of their respective holders. Use of the does not imply any affiliation or endorsement by them.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210427005860/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
